Fig. 2
a Reaction involving GLS and the inhibition via CB839. b Dose response curve of IDH1mut glioma cell lines and IDH1mut fibrosarcoma (HT1080) against increasing concentrations of CB839. c Growth rate of patient-derived IDH1mut glioma cell lines at different concentrations of Gln in cell culture media. d Growth rate of patient-derived IDH1mut glioma cell lines over time upon addition of 1 μM CB839 (data displayed as mean ± SD, n = 3 for each time point). e Synergy analysis for the 3 patient-derived IDH1mut glioma cell lines under 16 different combinations of CB839 and AGI5198 for 72 h based on growth inhibition (n = 3 for each combination). Data displayed as a heat map for the visualization of delta scores for the dose regions. ZIP synergy scores included at the top of each heat map for each cell line. f Quantification of Glu and Gln via 1H NMR under CB839 treatment vs DMSO controls. (n = 3 for each concentration, drug or time point tested, data displayed as mean ± SD; *p < 0.05; **p < 0.005; ***p < 0.001 from a t test unless otherwise indicated)